G
Guangdong Taienkang Pharmaceutical Co Ltd
SZSE:301263
Guangdong Taienkang Pharmaceutical Co Ltd
SZSE:301263
Price:
33
CNY
3.61%
Market Closed
Market Cap:
¥14B
Relative Value
The Relative Value of one Guangdong Taienkang Pharmaceutical Co Ltd stock under the Base Case scenario is hidden CNY. Compared to the current market price of 33 CNY, Guangdong Taienkang Pharmaceutical Co Ltd is hidden .
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Guangdong Taienkang Pharmaceutical Co Ltd Relative Value
HIDDEN
Multiples Across Competitors
Competitors Multiples
Guangdong Taienkang Pharmaceutical Co Ltd Competitors
Guangdong Taienkang Pharmaceutical Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
G
|
Guangdong Taienkang Pharmaceutical Co Ltd
SZSE:301263
|
14B CNY | 20.7 | 600.1 | 53 825.3 | 53 825.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
997.2B USD | 15.3 | 48.3 | 32.5 | 34.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.6B USD | 6.1 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
281.1B CHF | 4.6 | 30 | 12.7 | 14.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
303.5B USD | 4.7 | 16.6 | 10.4 | 12.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
230.9B CHF | 5.3 | 21.2 | 13.1 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.1B GBP | 5.2 | 32.1 | 15.3 | 22.4 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK | 4.2 | 12.7 | 9.3 | 11 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.7B USD | 2.5 | 19.9 | 7.4 | 9.9 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.6B USD | 2.6 | 17.8 | 6.9 | 8.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
